CSL Limited (ASX:CSL – Get Free Report) insider Robert Cuthbertson bought 132 shares of CSL stock in a transaction dated Friday, August 22nd. The shares were acquired at an average cost of A$216.60 per share, with a total value of A$28,590.94.
CSL Price Performance
The company has a debt-to-equity ratio of 64.46, a current ratio of 1.86 and a quick ratio of 1.68. The company has a market cap of $77.43 billion, a P/E ratio of 28.02, a price-to-earnings-growth ratio of 1.29 and a beta of 0.32.
CSL Increases Dividend
The company also recently disclosed a Final dividend, which will be paid on Thursday, October 2nd. Investors of record on Thursday, October 2nd will be paid a $2.485 dividend. The ex-dividend date of this dividend is Monday, September 8th. This represents a yield of 113.0%. This is an increase from CSL’s previous Final dividend of $2.20. CSL’s dividend payout ratio is currently 50.38%.
About CSL
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
Read More
- Five stocks we like better than CSL
- What is the S&P/TSX Index?
- DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?
- Insider Trades May Not Tell You What You Think
- Engines to AI: Cummins’ Surprising Growth Driver
- Compound Interest and Why It Matters When Investing
- Smaller Industrials Names Seeing Surging Growth: Here’s Why
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.
